Carbapenem-Resistant Enterobacteriaceae Infection Clinical Trial
Official title:
Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against Metallo-β-lactamases (MBL) producing Enterobacterales in vivo. The investigators then use CRISPR/Cas9 technology to remove Enterobacteriaceae bacteria resistance and virulence genes
Clinical information of subjects, including diseases, departments, medication history, days of hospitalization, and treatment outcomes will be collected; Bacterial species names will be identified and drugs sensitivity will be detected; For patients with bloodstream infection of MBL-producing Enterobacterales, ceftazidime-avibactam (CAZ-AVI) was administered at the dose of 2.5 g every 8 hours and aztreonam (ATM) at the dose of 2 g every 8 hours. The primary outcome measure was 30-day all-cause mortality, while secondary outcomes were clinical failure at day 14 and length of stay (LOS) after bloodstream infection diagnosis. Cox regression analysis, including a propensity score (PS) for receiving CAZ-AVI plus ATM, was conducted to assess the primary and secondary outcomes. The CRISPR/Cas9 gene curation technology was used to eliminate the drug resistance and virulence factors of Enterobacteriaceae in the mouse intestinal colonization model. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06051513 -
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
|
N/A | |
| Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
| Completed |
NCT04146337 -
Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae
|
Phase 2/Phase 3 | |
| Completed |
NCT04167228 -
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
|
||
| Terminated |
NCT04876430 -
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
|
Phase 2/Phase 3 | |
| Enrolling by invitation |
NCT03924934 -
Community-associated Highly-Resistant Enterobacterales
|
||
| Recruiting |
NCT04583098 -
The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
|
||
| Recruiting |
NCT04535661 -
Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
|
||
| Withdrawn |
NCT04785924 -
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
|
Phase 4 | |
| Terminated |
NCT05258851 -
Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
|
Phase 3 | |
| Not yet recruiting |
NCT04746222 -
Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04014413 -
Safety and Efficacy of Fecal Microbiota Transplantation
|
N/A | |
| Recruiting |
NCT05871476 -
Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals
|
N/A | |
| Terminated |
NCT05210387 -
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
|
N/A | |
| Not yet recruiting |
NCT06210542 -
Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
|
||
| Not yet recruiting |
NCT05981430 -
Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae
|
N/A | |
| Recruiting |
NCT06258551 -
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
|
||
| Recruiting |
NCT05979545 -
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
|
Phase 4 | |
| Completed |
NCT04790565 -
Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae
|
Phase 2/Phase 3 |